Lipid Replacement Therapy with a Glycophospholipid Formulation with NADH and CoQ10 Significantly Reduces Fatigue in Intractable Chronic Fatiguing Illnesses and Chronic Lyme Disease Patients

Garth L. Nicolson, Robert Settineri, Rita Ellithorpe

Department of Molecular Pathology, The Institute for Molecular Medicine, Huntington Beach, USA.
Sierra Research, Irvine, USA.
Tustin Longevity Center, Tustin, USA.

DOI: 10.4236/ijcm.2012.33034                

Abstract

Objectives: A preliminary open label study was initiated to determine if a combination oral supplement containing a mixture of phosphoglycolipids, coenzyme Q10 and microencapsulated NADH could affect fatigue levels in long-term patients with intractable fatigue. Fatigue was determined by the validated Piper Fatigue Scale before, during and after the trial. Participants included 58 patients (30 females and 28 males) with chronic fatigue syndrome/myalgic encephalomyelitis, chronic Lyme disease or other fatiguing illnesses, such as fibromyalgia syndrome or Gulf War illness. These patients had been symptomatic for an average of 17.1 ± 0.6 years, had been seen by many physicians (15.2 ± 0.7) and had used many other supplements and drugs (35.4 ± 2.7) without apparent reductions in their fatigue. Results: Participants in the study responded to the combination test supplement, showing a 30.7% reduction in overall fatigue within 60 days (P< 0.001). Analysis of subcategories of fatigue indicated that there were significant improvements in the ability to complete tasks and activities as well as significant improvements in mood and cognitive abilities. Regression analysis of the data indicated that reductions in fatigue were gradual, consistent, and occurred with a high degree of confidence (R² = 0.960). The data also suggested that further reductions were likely if the participants had continued the supplement beyond the 8-week trial. Males responded slightly better to the combination supplement than females, and the patients with the most severe forms of fatigue responded slightly better than those with milder fatigue, independent of their diagnosis. Conclusions: The combination supplement was a safe and effective method to significantly reduce fatigue in long-term patients with intractable chronic fatigue.

Keywords

Fatigue; Chronic Fatigue Syndrome; Lyme Disease; CoQ10; NADH; Phospholipids

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	D. Chambers, A.-M. Bagnall, S. Hempel and C. Forbes, “Interventions for the Treatment, Management and Rehabilitation of Patients with Chronic Fatigue Syndrome/ Myalgic Encepthalomyelitis: An Updated Systematic Review,” Journal of the Royal Society of Medicine, Vol. 99, No. 10, 2006, pp. 506-520. doi:10.1258/jrsm.99.10.506
[2]	S. Reid, T. Chalder, A. Cleare, M. Hotopf and S. Wessley, “Chronic Fatigue Syndrome,” Clinical Evidence, Vol. 2011, 2011, p. 1101.
[3]	J. D. Morrison, “Fatigue as a Presenting Complaint in Family Practice,” Journal of Family Practice, Vol. 10, No. 5, 1980, pp. 795-801.
[4]	K. Kroenke, D. R. Wood, A. D. Mangelsdorff, N. J. Meier and J. B. Powell, “Chronic Fatigue in Primary Care: Prevalence, Patient Characteristics, and Outcome,” Journal of the American Medical Association, Vol. 260, No. 7, 1988, pp. 929-934. doi:10.1001/jama.1988.03410070057028
[5]	D. Purvis, S. Gonsalves and P. A. Deuster, “Physiological and Psychological Fatigue in Extreme Conditions: Overtraining and Elite Athletes,” Physical and Medical Rehabilitation, Vol. 2, No. 5, 2010, pp. 442-450.
[6]	G. L. Nicolson and R. Settineri, “Lipid Replacement Therapy: A Functional Food Approach with New Formulations for Reducing Cellular Oxidative Damage, Cancer-Associated Fatigue and the Adverse Effects of Cancer Therapy,” Functional Foods in Health and Disease, Vol. 1, No. 4, 2011, pp. 135-160.
[7]	A. J. Knicker, I. Renshaw, A. R. Oldham and S. P. Cairns, “Interactive Processes Link the Multiple Symptoms of Fatigue in Sports Competition,” Sports Medicine, Vol. 41, No. 4, 2011, pp. 307-328. doi:10.2165/11586070-000000000-00000
[8]	M. D. Brand and D. G. Nicholis, “Assessing Mitochondrial Dysfunction in Cells,” Biochemical Journal, Vol. 435, No. Pt2, 2011, pp. 297-312. doi:10.1042/BJ20110162
[9]	M. R. Duchen and G. Szabadkai, “Roles of Mitochondria in Human Disease,” Essays in Biochemistry, Vol. 47, 2010, pp. 115-137. doi:10.1042/bse0470115
[10]	B. Halliwell, “Oxidative Stress, Nutrition and Health,” Free Radical Research, Vol. 25, No. 1, 1996, pp. 57-74.
[11]	J. Montero, M. Mari, A. Colell, A. Morales, G. Basanez, C. Garcia-Ruiz and J. C. Fernandez-Checa, “Cholesterol and Peroxidized Cardiolipin in Mitochondrial Membrane Properties, Permeabiliza-tion and Death,” Biochimica Biophysica Acta, Vol. 1797, No. 6-7, 2010, pp. 1217-1224.
[12]	G. L. Nicolson, “Lipid Replacement as an Adjunct to Therapy for Chronic Fatigue, Anti-Aging and Restoration of Mitochondrial Function,” Journal of the American Nutraceutical Association, Vol. 6, No. 3, 2003, pp. 22-28.
[13]	R. M. Adibhatla and J. F. Hatcher, “Lipid Oxidation and Peroxidation in CNS Health and Disease: From Molecular Mechanisms to Therapeutic Opportunities,” Antioxidant and Redox Signaling, Vol. 12, No. 1, 2010, pp. 125-169. doi:10.1089/ars.2009.2668
[14]	T. Kanno, E. E. Sato, S. Muranaka, H. Fujita, T. Fujiwara, T. Utsumi, M. Inoue and K. Utsumi, “Oxidative Stress Underlies the Mechanism for Ca(2+)-Induced Permeability Transition of Mitochondria,” Free Radical Research, Vol. 38, No. 1, 2004, pp. 27-35. doi:10.1080/10715760310001626266
[15]	E. Stadtman, “Introduction to Serial Reviews on Oxidatively Modified Proteins in Aging and Disease,” Free Radical Biology and Medicine, Vol. 32, No. 9, 2002, p. 789. doi:10.1016/S0891-5849(02)00764-5
[16]	L. Castro and B. A. Freeman, “Reactive Oxygen Species in Human Health and Disease,” Nutrition, Vol. 17, No. 2, 2001, pp. 295-307. doi:10.1016/S0899-9007(00)00570-0
[17]	J. H. Huang and D. A. Hood, “Age-Associated Mitochondrial Dysfunction in Skeletal Muscle: Contributing Factors and Suggestions for Long-Term Interventions,” IUBMB Life, Vol. 61, No. 3, 2009, pp. 201-214. doi:10.1002/iub.164
[18]	K. Green, M. D. Brand and M. P. Murphy, “Prevention of Mitochondrial Oxidative Damage as a Therapeutic Strat- egy in Diabetes,” Diabetes, Vol. 54, Suppl. 1, 2004, pp. S110-S118.
[19]	K. Jomova, D. Vondrakova, M. Lawson and M. Valko, “Metals, Oxidative Stress and Neurodegenerative Disorders,” Molecular and Cellular Biochemistry, Vol. 345, No. 1-2, 2010, pp. 91-104. doi:10.1007/s11010-010-0563-x
[20]	G. L. Nicolson and R. R. Ellithrope, “Lipid Replacement and Antioxidant Nutritional Therapy for Restoring Mitochondrial Function and Reducing Fatigue in Chronic Fatigue Syndrome and Other Fatiguing Illnesses,” Journal of Chronic Fatigue Syndrome, Vol. 13, No. 1, 2006, pp. 57-68. doi:10.1300/J092v13n01_06
[21]	B. F. Piper, A. M. Linsey and M. J. Dodd, “Fatigue Mechanism in Cancer,” Oncology Nursing Forum, Vol. 14, 1987, pp. 17-23.
[22]	B. F. Piper, S. L. Dribble and M. J. Dodd, “The Revised Piper Fatigue Scale: Psychometric Evaluation in Women with Breast Cancer,” Oncology Nursing Forum, Vol. 25, 1998, pp. 667-684.
[23]	J. M. Bland and D. G. Altman, “Statistical Notes: Cronbach’s Alpha,” British Medical Journal, Vol. 314, No. 7080, 1997, p. 572. doi:10.1136/bmj.314.7080.572
[24]	B. M. Crothers, A. K. Jain, K. L. De Meirleir, D. L. Peterson, N. G. Klimas, A. M. Lerner, A. C. Bested, P. FlorHenry, P. Joshi, A. C. P. Powles, J. A. Sherkey and M. I. van de Sande, “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols,” Journal of Chronic Fatigue Syndrome, Vol. 11, No. 1, 2003, pp. 7-116.
[25]	J. J. Burrascano Jr., “Advanced Topics in Lyme Disease: Diagnostic Hints and Treatment Guidelines for Lyme and Other Tick-Borne Illnesses,” 16th Edition, International Lyme and Associated Diseases Society, Bethesda, 2008, pp. 1-37.
[26]	R. R. Ellithorpe, R. Settineri and G. L. Nicolson, “Reduction of Fatigue by Use of a Dietary Supplement Containing Glycophospholipids,” Journal of the American Nutraceutical Association, Vol. 6, No. 1, 2006, pp. 23-28.
[27]	G. L. Nicolson, R. R. Ellithorpe, C. Ay-son-Mitchell, B. Jacques B and R. Settineri, “Lipid Re-placement Therapy with a Glycophospholi-pid-antioxidant-vitamin Formulation Significantly Reduces Fatigue within One Week,” Journal of the American Nutraceutical Association, Vol. 13, No. 1, 2010, pp. 11-15.
[28]	M. Agadjanyan, V. Vasilevko, A. Ghochi-kyan, P. Berns, P. Kesslak, R. Settineri and G. L. Nicolson, “Nutritional Supplement (NTFactor) Restores Mito-chondrial Function and Reduces Moderately Severe Fatigue in Aged Subjects,” Journal of Chronic Fatigue Syn-drome, Vol. 11, No. 3, 2003, pp. 23-36.
[29]	M. Seidman, M. J. Khan, W. X. Tang and W. S. Quirk, “Influence of Lecithin on Mitochondrial DNA and Age-Related Hearing Loss,” Otolaryngology and Head and Neck Surgery, Vol. 127, No. 3, 2002, pp. 138-144. doi:10.1067/mhn.2002.127627
[30]	L. Colodny, K. Lynch, C. Farber, S. Papish, K. Phillips, M. Sanchez, K. Cooper, O. Pickus, D. Palmer, T. B. Percy, M. Faroqui and J. B. Block, “Results of a Study to Evaluate the Use of Propax to Reduce Adverse Effects of Chemotherapy,” Journal of the American Nutraceutical Association, Vol. 3, No. 1, 2000, pp. 17-25.
[31]	G. L. Nicolson, “Lipid Replacement Therapy: A Nutraceutical Approach for Reducing Cancer-Associated Fatigue and the Adverse Effects of Cancer Therapy while Restoring Mitochondrial Function,” Cancer and Metastasis Reviews, Vol. 29, No. 3, 2010, pp. 543-552. doi:10.1007/s10555-010-9245-0
[32]	L. M. Forsyth, H. G. Preuss, A. L. MacDowell, L. Chiazze Jr., G. D. Birkmayer and J. A. Bellanti, “Therapeutic Effects of Oral NADH on the Symptoms of Patients with Chronic Fatigue Syndrome,” Annals of Allergy, Asthma and Immunology, Vol. 82, No. 2, 1999, pp. 185-191. doi:10.1016/S1081-1206(10)62595-1
[33]	D. Colquhoun and S. Senn, “Is NADH Effective in the Treatment of Chronic Fatigue Syndrome?” Annals of Allergy, Asthma and Immunology, Vol. 84, No. 6, 2000, pp. 639-640. doi:10.1016/S1081-1206(10)62421-0
[34]	D. Chambers, A. M. Bagnall, S. Hempel and C. Forbes, “Interventions for the Treatment, Management and Rehabilitation of Patients with Chronic Fatigue Syndrome/ Myalgic Ence-phalomyelitis: An Updated Systematic Re- view,” Journal of the Royal Society of Medicine, Vol. 99, No. 10, 2006, pp. 506-520. doi:10.1258/jrsm.99.10.506
[35]	M. L. Santaella, I. Font and O. M. Disdier, “Comparison of Oral Nicotinamide Adenine Dinucleotide (NADH) versus Conventional Therapy for Chronic Fatigue Syndrome,” Puerto Rico Health Science Journal, Vol. 23, No. 2, 2004, pp. 89-93.
[36]	J. Alegre, J. M. Rosés, C. Javierre, A. Ruiz-Baqués, M. J. Segundo and T. F. de Sevilla, “Nicotinamide Adenine Dinucleotide (NADH) in Patients with Chronic Fatigue Syndrome,” Reviews Clinica Espa?a, Vol. 210, No. 6, 2010, pp. 284-288. doi:10.1016/j.rce.2009.09.015
[37]	P. Belenky, K. L. Bogan and C. Brenner, “NAD+ Metabolism in Health and Disease,” Trends in Biochemical Science, Vol. 32, No. 1, 2007, pp. 12-19. doi:10.1016/j.tibs.2006.11.006
[38]	L. Chen, R. Petrelli, K. Felczak, G. Gao, L. Bonnac, Y. S. Yu, E. M. Bennett and K. W. Pankiewicz, “Nicotinamide Adenine Dinucleotide Based Therapeutics,” Current Medicinal Chemistry, Vol. 15, No. 7, 2008, pp. 650-670. doi:10.2174/092986708783885282
[39]	W. Ying, “NAD+ and NADH in Cellular Functions and Death,” Frontiers in Bioscience, Vol. 11, 2006, pp. 3129-3148. doi:10.2741/2038
[40]	N. Kashihara, Y. Haruna, V. K. Kondeti and Y. S. Kanwar, “Oxidative Stress in Diabetic Nephropathy,” Current Medicinal Chemistry, Vol. 17, No. 34, 2010, pp. 4256-4269. doi:10.2174/092986710793348581
[41]	C. M. Quinzii and M. Hirano, “Coenzyme Q and Mitochondrial Disease,” Developmental Disabilities Research Reviews, Vol. 16, No. 2, 2010, pp. 183-188. doi:10.1002/ddrr.108
[42]	G. P. Littarru and L. Tiano, “Clinical Aspects of Coenzyme Q10: An Update,” Nutrition, Vol. 26, No. 3, 2010, pp. 250-254. doi:10.1016/j.nut.2009.08.008
[43]	D. Orsucci, M. Filosto, G. Siciliano and M. Mancuso, “Electron Transfer Mediators and Other Metabolites and Cofactors in the Treatment of Mitochondrial Dysfunction,” Nutrition Reviews, Vol. 67, No. 9, 2009, pp. 427-438. doi:10.1111/j.1753-4887.2009.00221.x
[44]	M. Mancuso, D. Orsucci, L. Volpi, V. Calsolaro and G. Siciliano, “Coenzyme Q10 in Neuromuscular and Neurodegenera-tive Disorders,” Current Drug Targets, Vol. 11, No. 1, 2010, pp. 111-121. doi:10.2174/138945010790031018
[45]	M. A. Tarno-polsky, “The Mitochondrial Cocktail: Rationale for Combined Nutraceutical Therapy in Mitochondrial Cytopathies,” Advances in Drug Delivery Reviews, Vol. 60, No. 13-14, 2008, pp. 1561-1567. doi:10.1016/j.addr.2008.05.001
[46]	S. Beg, S. Javed and K. Kohli, “Bioavailability Enhacement of Coenzyme Q10: An Extensive Review of Patents,” Recent Patents on Drug Delivery and Formulation, Vol. 4, No. 3, 2010, pp. 245-255. doi:10.2174/187221110793237565
[47]	S. Myhill, N. E. Booth and J. McLaren-Howard, “Chronic Fatigue Syndrome and Mitochondrial Dysfunction,” International Journal of Clinical and Experimental Medicine, Vol. 2, No 1, 2009, pp. 1-16.